Cigarette smoking remains an important risk factor for premature cardiovascular disease and its many complications. There are clear benefits from treating tobacco dependence on the rate of clinical outcomes. In addition to behavioral therapies, various pharmacologic strategies have been developed to help achieve this goal. First-line therapies include nicotine replacement, bupropion and varenicline, a partial nicotine antagonist. Second-line treatments include clonidine and nortriptyline. Additional treatment strategies with less proven efficacy include monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, opioid receptor antagonists, bromocriptine, anti-anxiety drugs, nicotinic receptor antagonists (e.g. mecamylamine) and glucose tablets. Various approaches under investigation include inhibitors of the hepatic P450 enzyme (e.g. methoxsalen), cannabinoid-1 receptor antagonists (e.g. rimonabant), and nicotine vaccines.
Smoking and coronary artery disease
During World War I, cigarette smoking escalated and a sharp increase in the incidence of cardiovascular disease was noted [US Department of Health and Human Services, 1990 Services, , 1983 . However, it was not until 1958 that the first major epidemiological study demonstrated a strong correlation between smoking and cardiovascular disease [Hammond and Horn, 1958] . The study found that the risk of dying from coronary artery disease (CAD) was 70% greater in smokers than in nonsmokers. Although not providing definitive evidence that tobacco smoke was responsible for the increased coronary risk, it prompted the first antismoking measures by the Surgeon General in the 1964 report [US Public Health Service, 1964] . Accumulating evidence in subsequent years led to the 1979 report proposing a definite association between smoking and CAD [US Department of Health, Education, and Welfare, 1979] .
The harmful effects of smoking cigarette or cigars are not just confined to CAD prevalence and incidence. The practice also accelerates the development of other atherosclerotic vascular diseases [Matetzky et al. 2000; Jee et al. 1999] and can greatly increase the risk of acute coronary events, particularly sudden cardiac death (SCD) [Teo et al. 2006; Al-Delaimy et al. 2002; Jacobs et al. 1999a] . Evidence suggests that cigarette smoking is an independent predictor of SCD in patients with known CAD [Escobedo and Caspersen, 1997; Escobedo and Zack, 1996 ].
Smoking has also been shown to increase the risk of hospitalization for heart failure, myocardial infarction and death in patients with left ventricular dysfunction [Suskin et al. 2001 ].
Patients with CAD who quit smoking are at no greater risk of SCD than those who never smoked [Critchley and Capewell, 2003; Goldenberg et al. 2003 ]. Cessation of cigarette smoking has been estimated to increase the life expectancy among smokers who stopped at the age of 35 years compared with those who continued to smoke by 6.9 to 8.5 years for men and 6.1 to 7.7 years for women [Taylor et al. 2002] . For patients with left ventricular dysfunction, a 41% reduction in all-cause mortality has been observed in those who stop smoking compared to those who continued, there being no significant difference between ex-smokers and individuals who had never smoked [Suskin et al. 2001] . Smoking cessation appears to be a more powerful risk-factor intervention for coronary artery protection than dietary modifications [Anthonisen et al. 2005; Ludvig et al. 2005; Fichtenberg and Glantz, 2000; Jacobs et al. 1999b ]. Aggressive smokingcessation intervention has proved superior to a conservative approach for smokers who had undergone coronary artery bypass surgery [Hilleman et al. 2004] .
The life-threatening effects of smoking are attributed to increased sympathetic outflow [Narkiewicz et al. 1998 ] and heightened activation of the blood coagulation system [Hioki et al. 2001; Fisher et al. 2000; Newby et al. 1999] . The biomarkers of inflammation and atherosclerotic disease, high-sensitivity C-reactive protein and fibrinogen in blood, and 24-hour urine 8-epi-prostaglandin F2 and 11-dehydrothromboxane B2 are elevated in smokers compared with nonsmokers [Zedler et al. 2006 ]. Homocysteine is another biomarker of cardiovascular risk that has been shown to be elevated in the blood of smokers [Sobczak et al. 2004 ]. These biomarkers are thought to be involved in the mechanism promoting atherosclerotic disease progression via endothelial dysfunction [Bazzano et al. 2003 ]. Endothelial dysfunction is not only a precursor of CAD, but can also result in peripheral artery disease [Lu and Creager, 2004] , chronic renal disease [Stenvinkel, 2003] , and erectile dysfunction [Rodriguez et al. 2005] . Disturbingly, elevated levels of these biomarkers have also been detected in individuals exposed to second-hand smoke [Sobczak et al. 2004; Panagiotakos et al. 2004] .
Mechanisms of nicotine addiction
The benefits of smoking cessation include not only the reduction in cardiovascular risk, but also the risk of pulmonary disease and cancer. Ethnic differences in risk have been identified: Japanese smokers are least susceptible to lung cancer and African-Americans have a lower incidence of and higher mortality from chronic pulmonary disease than Caucasian Americans, but a higher incidence of and higher mortality from lung cancer [Sellers, 1998] . Although sociocultural factors may be contributory, there may be ethnic differences in nicotine metabolism that may contribute to nicotine addiction.
Nicotine addiction is a complex biopsychosocial problem. Once an addiction to nicotine develops, it is difficult to break. Cessation rates are very low when compared with the proportion of smokers who wish to stop, and repeatedly try to do so [Stapleton, 1998] . The effects of nicotine are centrally mediated, with biochemical and physiological functions reinforcing drug-taking behavior [Pomerleau, 1992] . Smoking motives scales allow the measurement of private events mediated by the proposed neuroregulatory effects of nicotine on neuropetides [Pomerleau and Pomerleau, 1984] . Questionnaires have been used to identify pharmacological and nonpharmacological motives for smoking. The most commonly identified motives are classified as automatic (ATM), addictive (ADD), sedative (SED), stimulatory (STM), psychosocial (SOC), indulgent (IND) and sensorimotor manipulation (SMM). In 1974, it was proposed that social and other nonpharmacological rewards motivate smoking initially and account for the stronger role of the SOC, IND and SMM motives early in a smoker's career [Russell et al. 1974] . By examining the pattern of correlations between factor scores and criterion variables, Tate suggested that ATM, ADD, SED and STM, and their underlying second-order factors, are more closely related to nicotine pharmacology and the mood-altering effects of nicotine than SOC, IND and SMM, and their underlying second-order factors [Tate, 1994] . Eventually the positive rewards of nicotine, mediated via its direct and indirect effects on the brain, exert more control as the smoker increasingly uses nicotine to modulate arousal and affective tone. This accounts for the stronger role of the SED and STM motives as the addiction progresses. Recent efforts have concentrated on elucidating some of the underlying neural circuits responsible for nicotine addiction. These include the brainstem pedunculopontine tegmental nucleus [Lanca et al. 2000 ] (also implicated in drug addiction) , activation of nicotinic acetylcholine receptors [Corringer et al. 2006] , and endocannabinoid receptors [Gonzalez et al. 2002] , gamma-aminobutyric acid (GABA) mechanisms [Zhu and Chiappinelli, 2002] and dopaminergic pathways [Mathieu-Kia et al. 2002] . A genetic mechanism has also been proposed to explain smoking initiation and nicotine dependence [Li, 2006; Picciotto and Corrigall, 2002 ].
An important component of reducing tobacco use in the general population is to prevent the development of nicotine addiction in the young people. It is also important to reduce the effects of passive smoking, which have been proved to be harmful to the cardiovascular system of nonsmokers and may aggravate the nicotine load in current smokers [Otsuka et al. 2001; He et al. 1999; Kato et al. 1999] .
Nicotine kinetics
Nicotine in cigarette smoke is absorbed in the pulmonary alveoli and passes into the blood [Benowitz, 1990] . Blood nicotine levels rise rapidly after smoking a cigarette (a phenomenon known as a 'nicotine boost') [Patterson et al. 2003] , with concentrations in the arterial plasma being about twice those in the venous plasma [Henningfield, 1993] . The extent of the nicotine boost can vary in different individuals [Patterson et al. 2003 ]. Thereafter, it takes less than 10 seconds for nicotine to reach the brain [Picciotto and Corrigall, 2002] . Blood levels of cotinine, the main metabolite of nicotine, are directly related to nicotine intake [Benowitz et al. 1997 ].
Smokers of less than five cigarettes per day have an average blood cotinine level of 54 ng/ml [Benowitz, 1994] . The reasonable threshold for the addictive cotinine is 50-70 ng/ml, but there appears to be no sharply demarcated value.
Nicotine withdrawal symptoms
In addicted patients, withdrawal symptoms develop within in a few hours of the last cigarette. Symptoms vary in different individuals, with some being relatively short-lasting and others persisting for several months (Table 1) [ Jarvis, 2004] . In most smokers, the addiction is aggravated by the need to avoid the discomfort of withdrawal.
Treatment of smoking cessation
Numerous factors should be taken into consideration when developing a rational approach to the treatment of nicotine addiction. First, the objectives of the treatment need to be established: namely, stopping smoking completely. Then, the appropriate medication needs to be identified to achieve this objective. The medication needs to be matched to the pathophysiology of the disease. Also, the optimal dosing regimen must be selected. The therapeutic outcome should be assessed periodically, and therapy adjusted to provide optimal benefits with minimal risk.
Smoking and nicotine can increase circulating cortisol and catecholamine levels. When considering smoking cessation therapy, allowance should be made for the pharmacologic effects of various adrenergic blockers and agonists during smoking withdrawal (Table 2) . 
Use of nicotine in smoking cessation
The severity of withdrawal symptoms that patients find distressing, and in some cases unacceptable, can be reduced by nicotine replacement therapy (NRT); thus, the urge to smoke cigarettes is reduced [Ford and Zlabek, 2005] . Patients using any form of NRT must be highly motivated and be prepared to stop smoking immediately. Ideally, they should also be supported by their healthcare provider and receive counseling. The odds of stopping are increased approximately 1.5-to 2-fold with NRT [Silagy et al. 2004] .
It has to be recognized that, even when abstinence for several months has been achieved, the risk of relapse remains high. Patients often may have to try several times to attain complete abstinence from smoking. Nicotine in the form of NRT can contribute to the pathophysiology of acute ischemic events in patients with CAD [Benowitz, 1991a] , but NRT is unlikely to be more harmful than cigarette smoking [Benowitz, 1995] . Similarly, the potential damage of NRT during pregnancy has to be weighed against known harmful effects of continuing smoking to the mother and the fetus [Coleman et al. 2004; Benowitz, 1991b , US Preventive Services Task Force, 2009 . The Surgeon General's report of 1988 concluded that NRT modifies withdrawal symptoms that could aggravate CAD during smoking cessation [US Department of Health and Human Services, 1988] .
Smokeless tobacco
The practice of taking snuff was particularly popular in the seventeenth century in Europe. In the USA, chewing tobacco was popular in the nineteenth century, but fell out of favor with the introduction of machine-rolled cigarettes. Smokeless tobacco, predominantly in the form of snuff or chewing tobacco, re-emerged as a popular form of tobacco use in the 1980s, particularly among male adolescents [Connolly et al. 1986 ].
Smokeless tobacco is associated with fewer and less serious health problems than cigarette smoking. However, the evidence regarding cardiovascular disease is not conclusive: some data from small-scale studies suggest that the risk of cardiovascular mortality and myocardial infarction is greater in smokeless tobacco users than in smokers [Critchley and Unal, 2004] . Higher nicotine levels detected in the blood of smokeless tobacco users than in smokers suggests that cardiovascular risk may be greater [Gupta et al. 2004 ]. However, further rigorous studies with adequate sample sizes are required to establish a firm link between smokeless tobacco and cardiovascular disease [Critchley and Unal, 2004] . Smokeless tobacco can cause other serious disease: for example, it is estimated to be responsible for 26 cases of oral cancer per 100 000 each year [US Department of Health and Human Services, 1986] . This is a very low incidence compared with the incidences of all smoking-related cancers and smoking-related lung cancer. A public-health policy that recognizes smokeless tobacco as an alternative to smoking would benefit individuals confronted with the unsatisfactory options of abstinence or continuing to smoke.
Nicotine patches
Transdermal nicotine delivery systems were approved by the US Food and Drug Administration (FDA) in 1991 as an adjunct to physician support for smoking cessation. In recent years, patches of various designs and different pharmacokinetic properties have become available [Frishman et al. 2003 ]. The low-dose patches are designed to produce blood nicotine levels that are less than those resulting from smoking [Gorsline et al. 1992] . The rate of nicotine absorption is maximal between 6 and 12 hours after application, with an absolute bioavailability of about 82%. Blood nicotine levels peak after 16 to 24 hours and then decline. The skin may serve as a reservoir for nicotine because about 10% of transdermal nicotine is systemically absorbed after the patch is removed.
A review of the findings of double-blind studies concluded that prescription nicotine patches are an effective aid to tobacco dependence treatment [Fiore et al. 1992 ]. However, since success rates varied greatly across studies, it was concluded that the results may be influenced by the nature and intensity of adjuvant smoking cessation counseling. An analysis of over-the-counter products showed that their use resulted in cessation rates by a factor of 2.8 compared with placebo and proved as effective when given on prescription (Table 3) . Higher-dose nicotine (44 mg/day) can achieve blood concentrations similar to those resulting from smoking [Dale et al. 1995; Jorenby et al. 1995] , and clinical data from 3575 patients suggest that smoking cessation may be enhanced [Tonnesen et al. Therapeutic Advances in Cardiovascular Disease 3 (4) 1999] . Patches are designed for 16-or 24-hour wear. No significant difference was found in cessation rates or withdrawal symptom with the two types, and both proved effective by more than doubling 6-month cessation rates [Daughton et al. 1991] .
The most frequently reported side effects with all 24-hour patches, but not with 16-hour formulations, are local skin irritation and contact sensitization. These events may be reduced by applying the patch to a different site each day. Use of 24-hour patches may also result in sleep disturbance; an effect that appears to be dosedependent [Page et al. 2006 ]. For patients experiencing sleep disturbances, a 16-hour patch may prove more acceptable. Alternatively, the 24-hour patch should be removed before bedtime. Patients who continue to smoke while using nicotine patches should be warned that they may experience nausea, abdominal pain, diarrhea, vomiting, dizziness, profuse perspiring, flushing, hearing and vision disturbances, confusion, weakness, palpitations, altered respiration and hypotension. All of these are signs and symptoms of nicotine toxicity. These events may be confused with nicotine withdrawal (Table 1) .
Transdermal nicotine has less effect on platelet activation and catecholamine release than does cigarette smoking; thus the use of patches as a smoking-cessation treatment in the patient with CAD is likely to be safer than cigarette smoking [Benowitz et al. 1993] . In a study using the transdermal nicotine patch or placebo in patients with known CAD and a history of smoking more than one pack of cigarettes per day, NRT proved safe [Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease, 1994] . This has been confirmed in another study [Kimmel et al. 2001 ]. However, use of nicotine patches should not be prescribed around the time of an acute myocardial infarction or in patients undergoing coronary artery surgical procedures [Meine et al. 2005 ].
Nicotine gums
Approved by the FDA in 1984 and now widely available on an over-the-counter basis, the nicotine strengths of the gums (nicotine polacrilex, nicotine resin complex) are 2 mg (1.4 mg nicotine extracted) or 4 mg (3.4 mg nicotine extracted). Highly addicted individuals, defined as smoking more than 25 cigarettes daily or with a Fagerstrom Tolerance Questionnaire Score 7 [Sachs, 1995] , should initially use the 4-mg strength; for others, the 2-mg nicotine gum is sufficient. The 4-mg strength increased cessation rates by a pooled factor of 2.2 over the 2-mg gum in highly dependent smokers, but showed no statistical difference over the 2-mg gum among low-dependence smokers [Silagy et al. 2004] . A summary of 6-month cessation rates with nicotine gum is provided in Table 3 . OTC, over the counter; NRT, nicotine replacement therapy. *Rates are given in percentages. Owing to differences in study design and in data collection, quit rates can be compared within rows, but not across rows. y These studies were surveys, not experimental trials. Because so few surveys were returned for carbon monoxide verification, these are self-reported quit rates. With carbon monoxide verification, they are likely to be somewhat lower. From: Hughes et al. [1999] . ( Papers cited in this table are referenced in Hughes et al.) .
It is recommended that normally 9-12 pieces of gum should be chewed daily, but the maximum can be 20-30. Even with extensive use of gum, chewers do not match the daily blood nicotine levels achieved by smoking cigarettes considering that the smoke from one average cigarette provides 0.8 mg. Unlike normal chewing gum, each piece should be chewed intermittently for about 30 minutes to allow absorption through the buccal mucosa. One piece of gum should provide nicotine replacement for 1-2 hours, but an additional piece may be chewed during the hour if a strong craving arises. The rate of nicotine release is dependent on the speed of chewing. Rapid chewing may result in the swallowing of nicotine-loaded saliva and can result in gastrointestinal side effects and headaches. It is important that patients should learn to chew slowly and understand the importance of self-titrating the nicotine dose. To assist in the so-called 'chew and park' technique, patients should be advised that they should stop chewing once a peppery taste or tingling in the mouth develops and only start chewing again once the sensation disappears.
Some people find that compliance with nicotine gum is difficult because of the need for oral manipulation, the unappealing flavor, jaw fatigue, jaw and mouth soreness, and headaches (because of excessive chewing). Other side effects that are usually only mild and transient include hiccups, burping and nausea. A low pH suppresses the buccal absorption of nicotine. Patients may also find it difficult to observe the recommended avoidance of carbonated drinks, coffee, beer, wine or any other acidic drinks for 15 minutes before and during gum chewing, especially if they previously associated such activities with smoking a cigarette [Henningfield et al. 1990 ]. Nicotine gum has been reported to be associated with habitual abuse but prospective data indicate that there is no increased risk of cardiovascular or other diseases with the use of nicotine gum for as long as 5 years, even with concurrent use of cigarettes Murray et al. 1996] .
Nicotine lozenges
Nicotine lozenges may be suitable for a patient who prefers oral NRT, but is intolerant of gum. An over-the-counter nicotine lozenge was approved by the FDA in 2002. In a placebo-controlled clinical trial, lozenges containing 2 and 4 mg nicotine were shown to be effective, with side effects similar to those of the gum [Shiffman et al. 2002] . The lozenge can also be 'parked' to facilitate absorption through the buccal mucosa.
Nicotine nasal spray
The spray is approved for clinical use as an aid to smoking cessation and for the relief of nicotine withdrawal symptoms. One dose consists of two squirts (one in each nostril), each squirt delivering 0.5 mg nicotine. The nicotine nasal spray can replace about 50% of the blood nicotine concentrations that occur with smoking. Smokers normally use one to two doses per hour, but this may be increased to 40 doses per day for 3 months. Peak concentrations of nicotine in the blood occur 5-l0 minutes after use [West et al. 1984] ; thus, delivery is faster than gum or an inhaler, but slower than cigarettes [Schneider et al. 1996 ]. The nasal spray can use used in association with nicotine patches to achieve increased efficacy [Bohadana et al. 2000 ] -a decrease in breakthrough cravings. Originally, it was thought that the dependence potential of nasal spray would be high because of the rapid nicotine absorption and the need for frequent administration. Studies have shown that this is not the case and have found no evidence of abuse with the product [Hughes, 1998; Schuh et al. 1997] . Cessation rates at 6 months of between 25% and 35% have been reported (Table 4 ).
Local irritation of the nose and throat are the most common side effects [Sutherland, 2002] . The incidence of moderate-to-severe irritation usually disappears or becomes mild within a few days of starting the spray. Other events include watery eyes, runny nose, coughing, and sneezing. Long-term nasal complications have not been described.
Nicotine inhaler
The nicotine inhaler became available by prescription in 1998 and was developed to mimic the hand-to-mouth ritual [Bolliger et al. 2000 ]. It looks very much like a cigarette and comprises a nicotine cartridge attached to a mouthpiece. Inhalers may need to puff, not inhale, vigorously and frequently to achieve a 30% replacement of blood nicotine levels; 80 deep puffs deliver 4 mg of nicotine. Unlike cigarettes, the inhaler delivers more nicotine by the buccal (36%) than the pulmonary (4%) route [Schneider et al. 2001] , with absorption being temperature-dependent with poor bioavailability below 10 C [Lunell et al. 1997 ]. The successful use of inhalers depends the number of doses taken; typically 6-16 cartridges per day are required to be successful in preventing smoking. As is common with other NRTs, the nicotine inhaler results in cessation rates that are double those achieved with placebo (Tables 3 and 4 ) .
If used concurrently with nicotine patches, high cessation rates may be achieved [Blondal et al. 1999] . Some patients experience local irritation, such as a burning sensation in the throat, as well as sneezing, coughing and hiccups. These side effects may compromise compliance with heavy use and may reduce the efficacy of an inhaler.
Nicotine partial antagonist
Varenicline Varenicline (Chantix Õ , Pfizer Inc.) is the most recently developed non-nicotine preparation and is a nicotine receptor partial agonist. The novel prescription drug for smoking cessation received FDA approval in May 2006, after a priority FDA review because of its potential benefit for public health. Varenicline is an analog of cytosine. Cytisine is derived from a weed called 'false tobacco' and is a competitive partial agonist at the nicotinic acetylcholine receptor (nAchR) [Etter, 2006; Slater et al. 2003 ].
Varenicline is a selective partial agonist for the 42 nAchR and does not bind to other common nicotine receptors and transporters. Varenicline also has moderate affinity for the 5-hydroxytryptamine-3 receptor. Stimulation of the 42 nAchR by varenicline produces some of the effects of nicotine, but reduces cravings and withdrawal symptoms Jorenby et al. 2006 ]. Unlike NRTs which require the patient to stop smoking, an individual who smokes while taking varenicline will experience a decline in the sense of satisfaction associated with smoking.
The recommended dose of varenicline is 1 mg twice daily. In the first week of administration, the dose is gradually increased from 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7 and then to 1 mg twice daily on day 8. The recommended duration of treatment is 12 weeks. If a patient succeeds in stopping smoking after 12 weeks, varenicline should be given for an additional 12 weeks to increase the likelihood of long-term smoking abstinence. Patients who are unsuccessful in stopping smoking after the initial therapy, or who relapse after the initial course of treatment, should be encouraged to try again after the factors that contributed to the relapse have been addressed.
In the clinical trials varenicline has been evaluated in over 3500 chronic cigarette smokers [ Gonzales et al. 2006; Jorenby et al. 2006; Oncken et al. 2006; Tonstad et al. 2006 ]. To date, there has been no direct comparison of varenicline with nicotine patches, but it has been compared with the other first-line nonnicotinic preparation, bupropion. Formal combination efficacy studies using varenicline and other smoking cessation therapies have not been performed. The smoking-cessation rate at the end of 12 weeks' twice-daily varenicline 1 mg treatment was twice that achieved with twicedaily bupropion 150 mg and was four-fold greater than that with placebo. At a 40-week post-treatment follow-up, those patients on varenicline who had stopped smoking at end of treatment were more likely to remain abstinent than those on placebo.
In clinical trials, varenicline was well tolerated. The most common side effects were nausea, changes in dreaming, constipation, flatulence and vomiting. No drug-drug interactions have been detected, although when used in conjunction with nicotine patches incidences of nausea, headache, and vomiting are greater than those experienced with the patch alone.
Recently the FDA issued an alert regarding postmarketing reports in patients of suicidal thoughts, aggressive and erratic behavior, and excessive drowsiness associated with varenicline [Kuehn, 2009] . A notice posted November 2008 on the FDA's MedWatch advises healthcare professionals to monitor patients taking varenicline for behavior and mood changes and recommends that people taking the drug should contact their physicians if they experience mood or behavioral changes. The FDA has also added a warning to the varenicline package insert about neuropsychiatric symptoms and exacerbations of pre-existing psychiatric illness associated with its use [Kuehn, 2009] .
Smoking itself is associated with psychiatric disease [Dierker and Donny, 2008; Goodwin et al. 2008; Breslau et al. 2005; Miller et al. 2000 ]. Psychiatric symptoms including suicide ideation and completed suicide have been associated with smoking and with smoking cessation. Therefore, it is not clear whether the psychiatric symptoms associated with the use of varenicline to treat tobacco dependence are caused by the drug itself or the disease. The benefits of using the drug to stop smoking may outweigh the risk [Anonymous, 2008] .
Non-nicotine preparations
Bupropion Bupropion is available in two sustained-release forms (Wellbutrin Õ and Zyban Õ [both Glaxo-Wellcome]), and a generic form. It is an atypical antidepressant with dopaminergic and adrenergic actions; bupropion was originally marketed for the treatment of depression. Evidence also suggests that bupropion antagonizes a brain nicotinic receptor and blocks the reinforcing effects of nicotine [Hays and Ebbert, 2003 ]; hence, a sustained-release formulation, Zyban Õ was developed specifically for use in smoking cessation [Patterson et al. 2008; Fossati et al. 2007; Colby and Gwaltney, 2007; Ahluwalia et al. 2002; Jorenby, 2002] . Zyban first became available in 1998. Using sustained-release bupropion for smoking cessation does not involve the replacement of nicotine and may be appropriate for patients who dislike or who have failed NRT. For patients interested in reducing rather than quitting smoking altogether, bupropion can help them to achieve this during the treatment course [Ahluwalia et al. 2002] . Bupropion also may reduce the time to the next attempt to stop and increase short-term abstinence rates [Hatsukami et al. 2004] . When combined with NRT, greater effects on smoking cessation are seen than with either treatment alone [Jorenby et al. 1999] . It may be especially beneficial for patients concerned about weight gain associated with stopping smoking, as buproprion appears to blunt this effect [Hays and Ebbert, 2003] . Within 1 week of starting bupropion, many smokers note that their craving for cigarettes is altered and their satisfaction from tobacco decreased.
Smokers using the sustained-released formulation of bupropion (which is approved for clinical use) begin treatment 1 week prior to the date they plan to stop smoking. Dose titration is performed, starting at 150 mg for 3-5 days before an increase to 150 mg twice daily. The recommended duration of treatment is 7-12 weeks, but this may be extended to 12 months to prevent relapse and dependent on the individual's nicotine withdrawal phase [Hays and Ebbert, 2003 ]. Its long-term safety for the treatment of chronic depression has already been determined. There is no rebound phenomenon upon abrupt discontinuation of the drug, because bupropion is a non-nicotine-based therapy. Some clinicians will use Wellbutrin XL Õ 150 mg once daily, which is Therapeutic Advances in Cardiovascular Disease 3 (4) off-label for tobacco dependence treatment and may decrease insomnia.
In comparison with a cessation rate of 19.05% with placebo, bupropion 100, 150 and 300 mg/ day for 7 weeks produced rates of 28.8%, 38.6% and 44.2%, respectively, in a study of more than 600 patients [Hurt et al. 1997 ]. A history of major depression was an exclusion criterion in this study, thus suggesting that the beneficial effect of bupropion was not explained by its antidepressant activity. Another study has shown that bupropion was equally effective in smokers whether or not they had a history of depression [Hayford et al. 1999] . In a randomized study of over 1500 smokers, 1-year cessation rates after bupropion and minimal-to-moderate counseling were between 23.6% and 33.2% [Swan et al. 2003 ]. The study also demonstrated that bupropion provided effective treatment in the primarycare setting and did not require intensive counseling.
Smoking cessation rates at 6-months were similar to those achieved with NRT and were greater than observed in placebo (Table 4 ) . In a study of patients with known cardiovascular disease, cessation rates were more than doubled in the bupropion than in the placebo group between 4 and 52 weeks after the start of treatment [Tonstad et al. 2003 ].
Side effects observed in clinical trials using the sustained-release formulation include insomnia (30-42%), headache (26%), and dry mouth (10.7%). Insomnia can be overcome by taking the evening dose more than 4 hours before bedtime. Initial studies with higher-dose, immediaterelease bupropion have shown a higher frequency of seizures. More recent data with sustainedrelease preparations at doses of 150 mg twice daily showed that the risk of seizures was no greater than that of typical antidepressants [Aubin, 2002] . Patients with a history of seizures or suicide ideation should not use bupropion [Kuehn, 2009] . Bupropion is also contraindicated if there is a history of head trauma, heavy alcohol use or anorexia. Furthermore, bupropion must not be used in combination with monoamine oxidase inhibitors or in patients with schizophrenia. Bupropion has been assigned a class C category for pregnancy by the FDA.
Bupropion can be used in combination with nicotine patches; a 1-year cessation rate of 25-30% has been recorded as opposed to 15-20% when monotherapy with counseling was employed [Prochazka, 2000] . It is the author's opinion that concurrent bupropion and nicotine patch use should be considered for patients who have failed prior therapy, have high levels of nicotine dependence, or a history of psychiatric problems.
Clonidine
Clonidine is an 2 adrenergic agonist developed originally as an antihypertensive agent [Prichard, 1988] , but it has also been recommended for the treatment for chronic pain syndromes, menopausal flushing, Tourette syndrome, opiate or alcohol abuse withdrawal and other neuropsychiatric conditions [Sandyk et al. 1987] . More recently, studies have investigated the use of clonidine as a smoking-cessation therapy [Covey and Glassman, 1991] . Clonidine suppresses the acute symptoms of nicotine withdrawal, such as tension, irritability, anxiety, cravings and restlessness.
Clonidine's recommended dose for smoking cessation is 100 mg given twice daily, but the drug can be titrated to a maximum of about 400 mg per day according to toleration. Treatment should commence before stopping smoking so that steady-state plasma concentrations can be achieved before the onset of nicotine withdrawal symptoms. The maximum duration of treatment should not be more than 3-4 weeks. Physicians should be vigilant to the potential for rebound hypertension on withdrawal in hypertensive patients; therefore, treatment should not be stopped abruptly but should be gradually downtitrated. A meta-analysis of ten small-scale and two large-scale trials revealed a trend for improved smoking cessation rates, although efficacy at 6 months was only demonstrated in one study [Covey and Glassman, 1991] .
Side effects have restricted the use of clonidine in smoking-cessation therapy to second-line treatment. The important adverse events include orthostatic hypotension, dizziness, fatigue, sedation and dry mouth. Situations where clonidine may be considered appropriate include the failure of NRT or bupropion, and the presence of multiple drug-abuse problems; this is because clonidine relieves the withdrawal symptoms of other drugs besides nicotine [Prichard, 1988] .
Clonidine might be used in combination with NRT or bupropion as its mechanism of action is different from that of either. However, to the author's knowledge, no relevant studies have been reported. Before it can be considered as a first-line therapy for smoking cessation, future studies will have to show that clonidine is clinically effective and is associated with fewer sideeffects than other treatments.
Nortriptyline
Nortriptyline is a noradrenergic tricyclic antidepressant drug that can have a beneficial impact on nicotine withdrawal symptoms. It is not approved by the FDA for nicotine dependence and should only be considered as second-line treatment for smoking cessation.
Nortriptyline, compared with placebo, doubled the continuous 1-year smoking abstinence rate from 12% to 24% [Hall et al. 1998 ] when used in association with intensive individual counseling sessions. Although excessive hunger and increased eating and drowsiness were unchanged, significant reductions in impatience, irritability/ anger, anxiety/tension, restlessness, and insomnia. An improvement in the ability to concentrate was noted in other studies [da Costa et al. 2002; Kahan, 1999] . One study found that 14% of nortriptyline-treated patients but only 3% in the placebo group remained abstinent after 6 months [Kahan, 1999] . The other study (n = 144) demonstrated a 6-month abstinence rate of 20.6% for nortriptyline and 5.3% for placebo [da Costa et al. 2002] . The overall efficacy of nortriptyline was similar to that of bupropion and appeared unrelated to nortriptyline's antidepressant activity. The study participants had histories of depression; thus, the findings may not be applicable to the general smoking population. An improved smoking-cessation rate has been recorded when nortriptyline was used in conjunction with nicotine patches [Prochazka et al. 2004] .
Side effects are frequent and include dry mouth, distortion or decrease in taste sensation, gastrointestinal disturbances, drowsiness and sleep disruption. Some patients report lightheadedness, shaky hands and blurry vision. Disturbances of cardiac rhythm can occur, and overdose can result in serious and possible life-threatening toxicity.
Selective serotonin reuptake inhibitors Selective serotonin reuptake inhibitors SSRIs are used to treat depression and anxiety, and to regulate mood. After smoking cessation, many people experience mood changes resembling subclinical depression. It is theoretically possible, therefore, that SSRIs such as fluoxetine, paroxetine or sertraline may help patients overcome these symptoms.
Fluoxetine 60 mg improved both the positive and negative mood states in one clinical trial conducted in smokers without clinically significant depression [Cook et al. 2004] . Doxepin, in a study of only 15 patients, resulted in significantly less craving for cigarettes [Murphy et al. 1990 ]. However, fluoxetine proved not to be effective as an adjunct to NRT, although it may be beneficial if a smoker is depressed [Blondal et al. 1999] .
Results of other studies evaluating fluoxetine, paroxetine or sertraline in the management of smoking cessation have failed to establish any benefit [Hughes et al. 2004 ]. In the light of these inconclusive findings, the use of SSRIs in smoking-cessation therapy is not currently recommended.
Monoamine oxidase inhibitors
Animal and human studies have shown that exposure to tobacco smoke reduces the levels of monoamine oxidase (MAO) in the brain [Fowler et al. 2003 ]. The reversible MAO type A inhibitor moclobemide, given at a doses of 400 mg/day for 2 months and 200 mg/day during the third month, has been evaluated when given as an aid to smoking cessation in heavily dependent smokers and proved successful. However, the study subjects tended to experience insomnia and dry mouth.
Under laboratory conditions, the MAO type B inhibitor selegiline reduced smoking behavior as well as cravings [Hughes et al. 2004] . At a daily dose of 10 mg for 8 weeks, a pilot study in hardto-treat smokers found that selegiline improved smoking-cessation rates and was well tolerated [George et al. 2003 ]. Further analysis showed 45% of the participants receiving selegiline had not smoked during the preceding week when questioned at the end of treatment [Zickler, 2003a] . When asked again 6 weeks later, 20% were still not smoking.
Bromocriptine
Researchers have hypothesized that dopamine mediates the reinforcing effects of stimulant drugs, including nicotine, suggesting that a dopamine antagonist could increase smoking and that an agonist could reduce smoking. Subfertile women (using bromocriptine to help conceive) were half as likely to smoke as those taking other drugs or those conceiving without medication [Foulds et al. 2004; Murphy et al. 2002] . In a laboratory study of heavy smokers, bromocriptine use was linked to reduced smoking [Foulds et al. 2004; Zickler, 2003b] .
Anxiolytics
The efficacy of benzodiazepine as a tobacco cessation treatment has not been demonstrated, and prolonged use of the drug may lead to physical and psychological dependence, so its use for smoking cessation is contraindicated. The results of treatment with a nonbenzodiazepine anxiolytic, such as buspirone, have been inconsistent, and the current recommendation is that this type of drug should be limited to the use of alternative, second-line treatment [Lauro and Paxeras, 2004] .
Glucose
Oral glucose tablets have been proposed as a possible aid to smoking cessation that would be very inexpensive and might be used by some smokers as well as or instead of medications. It is hypothesized that a single dose of nicotine will relieve hunger in a smoker so that over time smokers therefore come, in certain situations, to interpret sensations associated with hunger as craving for a cigarette. Some studies have shown that chewing glucose tablets can reduce the desire to smoke during abstinence. Definitive trials are now required, but given their low cost, glucose tablets may be a useful aid for some smokers [West, 2001] .
Upper airway stimulants
The stimulation of the sensory receptors located in the pharynx and larynx could contribute to tobacco addiction. Inhaled preparations of ascorbic acid, citric acid and extract of black pepper have been evaluated although currently no results are available to justify their current use [Lauro and Paxeras, 2004] .
Experimental formulations which can affect nicotine
Inhibition of the hepatic cytochrome P450 system As mentioned earlier, approximately 80% of nicotine is metabolized to the inactive metabolite cotinine by way of C-oxidation, and CYP2A6 is responsible for 90% of this process. Variations in the activity of this enzyme account for individual differences in the rate of nicotine metabolism and have been shown to influence various aspects of smoking behavior, such as the ability to start smoking and become addicted to tobacco, as well as the maintenance of higher or lower levels of tobacco use [Lauro and Paxeras, 2004] . Many individuals who lack the enzyme either do not smoke or smoke very little. Researchers theorized that if they could block the enzyme from being produced or prevent its activity, it would reduce a person's desire to smoke. The agent methoxsalen was shown to inhibit the metabolism of orally administered nicotine and reduce the rate of smoking in study subjects [Sellers et al. 2003 ]. The drug works to indirectly decrease the desire to smoke by slowing the removal of nicotine from the body, so individuals have less of an urge to smoke and therefore will have less exposure to it. In addition, CYP2A6 activates procarcinogens, so that blocking the enzyme may not only decrease smoking levels, but also may make cigarette smoke safer because there would be less activation of these procarcinogens. Research regarding this treatment approach is still in its early phase.
Nicotine vaccine
In the context of drug addiction, the aim of a therapeutic vaccine is to stimulate the production of specific antibodies that will fix the target drug and alter its pharmacokinetic properties [Riley et al. 2008] . The principal objective is to reduce the quantity of the substance available or its distribution to the brain. High doses of nicotine produce reward stimuli much greater than low doses and rapid delivery of nicotine to the brain stimulates a much greater reward response than slow delivery [Lauro and Paxeras, 2004] . For example, a cigarette produces a much greater reward response than a nicotine patch. The nicotine vaccine stimulates the production of nicotinespecific antibodies that can bind nicotine with a high affinity and fix it in plasma. Because of their high molecular weight these antibodies are too large to cross the blood-brain barrier so that the nicotine fixed by the antibody is thus blocked from entering the central nervous system [Lauro and Paxeras, 2004] . Nicotine is a small molecule that is not very antigenic. In order to augment the immune response, nicotine can be bound to larger molecules, usually proteins found in bacterial toxins. In animal studies, the nicotine vaccine has been shown to be effective in reducing the distribution of nicotine to the brain by 60% Pentel and Malin, 2002] . Vaccination of rats against nicotine has been shown to reduce nicotine distribution to the brain [Hieda et al. 1999; Lindblom et al. 2002] even with nicotine doses that are twice the estimated binding capacity of the antibodies. This suggests that the vaccine not only sequesters nicotine, but may also direct it away from the brain by some other mechanism [de Villiers et al. 2002] .
In animals, antibodies were produced to nicotine even with the continued administration of nicotine to the subject. Therefore, these vaccines could be used even in individuals continuing to smoke, and the antibodies would be present when a cessation attempt was made.
Some pharmaceutical companies are currently developing nicotine vaccines for human use [Foulds et al. 2004] . TA-NIC [Xenova Group, 2005] , a novel nicotine vaccine that has undergone phase 1 studies, has been shown to be safe and immunogenic when using up to six vaccinations during weeks 0-8, with a booster at 9 months [Xenova Group, 2005] . The TA-NIC vaccine has been shown to have a 12-month abstinence rate of 19-38% with 250 and 1000 mg doses versus 8% with placebo in clinical trials [Xenova Group, 2005] . Enrolment for a large phase IIb trial in the US was completed in October 2007. This placebo-controlled, doubleblind, multicenter study is evaluating the safety and efficacy of TA-NIC in managing smoking cessation when given in combination with current standard support treatment. The primary endpoint of the study is a 6-month smoking abstinence rate [Celtic Pharma, 2008] . Initial study results are expected shortly.
Nabi Pharmaceuticals has also developed a nicotine vaccine (Nic VAX), which is a nicotine recombinant Pneudomonoas aeruginosa exprotein A conjugate vaccine [Buchhalter et al. 2008 ]. Phase I studies have shown safety and antibody response up to 63 days postvaccination. Singledose vaccine produced antibodies within 7 days, which were maintained in the blood over 4 months [Nic-VAX, 2008] . In a phase II doubled-blinded, placebo controlled, randomized study with 68 smokers, the vaccine was found to be well tolerated, with side effects similar to placebo. Vaccine immunogenicity was dose-related, with the highest dose eliciting antibody concentrations within the anticipated range of efficacy [Nabi Biopharmaceuticals, 2006 ]. Preliminary reports showed that 38% of smokers taking the vaccine stopped smoking for at least 30 consecutive days versus 9% of placebo subjects. Patients were given four injections over a 6-month period. The results represented a vaccine-only effect, as patients were only given the vaccine without any supplemental treatment, behavioral support or counseling. The vaccine received 'fast track' designation from the FDA.
CYT-002-NicQb is a vaccine based on the viruslike particle formed by the recombination coat protein of the bacteriophage Qb. It is being developed by Cytos Biotechnology. Preclinical studies in mice have demonstrated the efficacy of CYT-002-NicQb in producing nicotine-specific antibodies and reducing penetration of the brain by circulating nicotine. In a phase I study, the vaccine produced an immunogenic response of 100% [Maurer and Bachmann, 2007] . In a phase II trial, abstinence correlated significantly with antibody levels as smokers in whom high antibody levels were achieved showed significant improvements in continuous abstinence over 6-and 12-month periods compared with subjects receiving placebo and subjects showing medium and low antibody levels [Maurer and Bachmann, 2007] . In those individuals who resumed smoking, there was no evidence for increased smoking activity to compensate for the neutralizing effect of nicotine [Buchhalter et al. 2008] .
With these vaccines, achievement of high antibody levels is essential for efficacy. Subjects often require multiple injections over 4-6 weeks to achieve sufficient antibody titers. In addition, there seems to be great interindividual variability in the immunogenicity of the vaccine, which could provide a challenge in clinical practice.
The clinical benefit for smokers with this approach is that in a vaccinated individual, nicotine will not have the same effect on the brain and thus smoking may not become addictive. The implications for current smokers as a tool for cessation, former smokers as a tool for relapse prevention and 'never smokers' (possibly the young) as a tool for primary prevention, are numerous. This vaccination has potential benefits for both pregnant smokers and the developing fetus as nicotine has been implicated as a neurotoxin in developing fetal tissues. Vaccinated pregnant smokers might be more likely to quit and remain abstinent, with a reduction of nicotine exposure to the brain of the fetus [Foulds et al. 2004; Keyler et al. 2003 ]. Additional studies are required to assure the safety and efficacy of the vaccine in humans.
Vaccination against nicotine appears very effective and poses relatively few side effects because the antibody itself does not appreciably enter the brain. Because nicotine vaccines target the drug rather than the brain, and the antibodies themselves do not cross the blood-brain barrier, immunization should circumvent the CNS side effects that limit the usable dosage of other medications for tobacco dependence. The antibodies are also highly specific for nicotine and do not bind other ligands, endogenous neurotransmitters or receptors. While the effects of the vaccine could be nullified with enough nicotine ingestion to overpower the antibody response produced, it is unlikely [Hall, 2002] . Possible target groups for the vaccine include an experimenting teenage population, a recently abstinent smoker or patients trying to quit smoking. In any case, the effect is similar, in that a risk factor for atherosclerosis is nullified.
Additional drugs under investigation

Rimonabant
Endocannabinoid receptors have recently been implicated in nicotine addiction [Gonzalez et al. 2002] . Hence, drugs affecting cannabinoid receptors may aid smoking cessation. The selective cannabinoid-1 receptor blockers (CB1) are thought to modulate systems in the brain that are altered by cigarette smoke [DiMarzo et al. 2004] . Rimonabant (Accomplia Õ , Sanofi-Synthelabo) is the first CB1 receptor and it is currently available in UK as an anti-obesity drug. In animals, rimonabant reduced selfadministration of nicotine and release of dopamine in the nucleus accumbens induced by nicotine [Cohen et al. 2005] . The drug has been proposed not only as an aid for smoking cessation, but also for the maintenance of abstinence [Tonstad, 2006] . Clinical trials have shown success regarding its use in smoking cessation; however, results from Europe showed that its use is associated with a significantly increased rate of psychiatric adverse effects, and the drug, as of now, will not be approved for clinical use in the United States.
Reboxetine
Reboxetine is a selective inhibitor of the norepinephrine transports, and also has been shown to be a noncompetitive antagonist of nAChRs. Animal studies have found that reboxetine inhibits nAChR function, suggesting that it may have potential as a smoking cessation agent [Foulds et al. 2004] . In rats, a reboxetine-induced decrease in nicotine self-administration has been observed [Rauhut et al. 2002] .
Naltrexone
Opioid treatments have been investigated for smoking cessation as the reinforcing properties of nicotine may be mediated through release of various neurotransmitters that impact on the endogenous opiate system. Naltrexone use in a laboratory study was associated with reduced number of cigarettes smoked, but the drug was associated with significant side effects, especially sedation [Epstein and King, 2004] . In a preliminary study, naltrexone in combination with NRT for smoking cessation reduced the likelihood of relapse, and the desire to smoke, and prevented weight gain following smoking cessation [Krishman-Sarin et al. 2003 ].
Vinyl GABA An anti-epilepsy drug called gamma vinyl-GABA has been shown to cause a rise of the transmitter dopamine in the brain's 'reward centers' and can stop the craving for nicotine in rats. It is being evaluated as an alternative approach for smoking cessation [Wickelgren, 1998] .
Mecamylamine
The antihypertensive and nicotine receptor antagonist mecamylamine has been assessed as part of a smoking cessation therapy along with NRT [Sutherland, 2002; Rose et al. 1994] . Two small studies have demonstrated the efficacy of mecamylamine when used precessation and continued postcessation [Lancaster and Stead, 2005] . It is unclear whether the benefit is greater with the combination than with nicotine alone, and larger studies are required before it can be recommended for smoking cessation.
GTS-21
GTS-21 (DMXB-A, anabasine) is a compound that binds selectively to the nAChR. In addiction, GTS-21 is a moderately potent antagonist at the alpha4-beta2 receptor. Dysfunction of the nAChR has been linked to a number of human diseases related to smoking, such as schizophrenia, attention-deficit disorder and Alzheimer's disease. The role of nAChR in smoking remains unclear. In animals it reduces the dopamine releasing and discriminative effects of nicotine [Cohen et al. 2003 ].
Conclusions
Cigarette smoking is strongly associated with an increased risk of developing CAD, COPD and cancer [Botteri et al. 2008] . Ex-smokers with CAD have significantly lower mortality, fewer ischemic events and better cardiac function than individuals with CAD who continue smoking [Kenfield et al. 2008; Strandberg et al. 2008; Cesaroni et al. 2008; Van Domburg et al. 2008; Lerman and Niaura, 2002 ; US Department of Health and Human Services, 1990 ]. Because of the clear health benefits of smoking cessation, the importance of encouraging patients to stop cannot be overemphasized [Burke et al. 2008; Christakis and Fowler, 2008; Dawood et al. 2008; Fiore and Jaen, 2008; Rigotti et al. 2008; Sabia et al. 2008; Steinberg et al. 2008; Thorndike et al. 2008; Gostin, 2008] . The effectiveness of current therapies to help smokers to achieve this goal is reflected in Medicare policies. Medicare currently reimburses healthcare providers for counseling regarding smoking cessation and, as of 1 January 2006, prescription smoking-cessation medications are now covered for eligible Medicare beneficiaries in accordance with the Medicare prescription drug benefit.
Nicotine, together with carbon monoxide and tar, is one of the substances in cigarette smoke that contributes to the increased mortality risk in smokers. Furthermore, nicotine appears to contribute most to the addictive nature of cigarette smoking. A variety of pharmaceutical nicotine formulations are available for use in replacement therapy for cigarette smoking to help smokers who wish to eliminate their addiction to smoking and nicotine [Epstein, 2008 , Frishman, 2007 Frishman et al. 2006 ]. NRT appears to be an effective and safe approach to smoking cessation, along with behavioral modification and other pharmacologic interventions, in patients with known CAD. Many new NRTs are available, and research is being undertaken to understand more fully the neural circuits and pathways involved in smoking and drug addiction. With this knowledge, we should be able to develop newer and better therapies. Currently, NRT with the nicotine patch and gum are firstline therapies in smoking cessation (Table 5 ) .
Varenicline, a nicotine receptor partial antagonist, was approved for use in smoking cessation as a first-line therapy; however, there may be an increase in suicide ideation with its use [Kuehn, 2009] . Bupropion, a non-nicotine therapy that was originally given to treat depression, is another first-line therapy that can be employed in combination with NRT. Another antidepressant, nortriptyline, has been shown to be as effective as bupropion, although it is not a first-line agent. The proven efficacy of bupropion and nortriptyline appears to occur independent of their antidepressant activities.
Research into genetics may provide an empirical approach, by enabling various pharmacologic treatments to be tailored to the individual with tobacco dependency [Kendler et al. 1999] .
Using genetic association studies of smoking initiation and dependence, genetic polymorphisms have been identified [Shields et al. 2005; Glantz and Annas, 2000; True et al. 1999] .
Pharmacogenetics may help to predict responses to different medications used as part of a smoking-cessation program. Nicotine in cigarette smoke is acknowledged as a pharmacologic substance and, as are other drugs, needs to be regulated [Rosner and Stampfer, 2006; Kessler, 2001] . Congress may soon grant permission for the FDA to regulate the nicotine content in tobacco products [Curfman et al. 2008 ].
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